Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector
Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models
The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
Antidepressant side effects vary widely among medications, impacting heart health, weight, and metabolism in distinct ways. If you're wondering how these drugs affect your body, a recent systematic review and network meta-analysis in The Lancet shows key differences. For ex...
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25
The CMS Annual Report 2024/25 highlights significant medical schemes affordability challenges in South Africa, where relevant healthcare expenditure per beneficiary surged by 8.70% year-on-year, far outpacing both contribution growth and general inflation. Solvency ratios have declined for three ...